Share and Follow
On Wednesday night, President Donald Trump took to the White House podium for a prime-time address, emphasizing what he called historic reductions in prescription drug prices. He detailed how the TrumpRx initiative and most-favored-nation drug pricing policies are set to roll out starting in January.
Trump told his fellow Americans, “I’m doing what no politician of either party has ever done – standing up to the special interest to dramatically reduce the price of prescription drugs.”
Trump elaborated on the TrumpRx program, building upon a series of agreements that have been in the works since late September. These agreements employ a most-favored-nation framework and direct-to-consumer sales, aiming to align U.S. drug prices with those of other countries for identical medications.
As reported by Breitbart News in November, Trump successfully negotiated with five major pharmaceutical giants—Pfizer, AstraZeneca, EMD Serono, Eli Lilly, and Novo Nordisk. These deals encompass a broad array of commonly prescribed drugs.
The initial agreement, forged with Pfizer on September 30, enabled state Medicaid programs to access most-favored-nation pricing. Additionally, consumers can now purchase several medications at significant discounts. For instance, the dermatitis ointment Eucrisa will be available at an 80 percent discount, the rheumatoid arthritis drug Xeljanz at 40 percent off, and the migraine treatment Zavzpret at a 50 percent reduction when purchased directly.
Trump’s comments on TrumpRx build on a series of agreements announced since late September that use a most-favored-nation framework and direct-to-consumer sales to tie U.S. drug prices to what is paid for the same medications in foreign countries.
In November, Breitbart News reported that Trump had reached deals with five major pharmaceutical companies—Pfizer, AstraZeneca, EMD Serono, Eli Lilly, and Novo Nordisk—covering a wide range of commonly used medications.
Under the first agreement, reached with Pfizer on September 30, state Medicaid programs gained access to most-favored-nation prices, while several drugs became available to consumers at steep discounts through direct purchase. The dermatitis ointment Eucrisa was slated to be offered at 80 percent off, rheumatoid arthritis drug Xeljanz at 40 percent off, and migraine medication Zavzpret at a 50 percent reduction when bought directly.
A follow-up deal with AstraZeneca on October 10 expanded the model to inhalers used to treat asthma and chronic obstructive pulmonary disease. According to the White House, BEVESPI AEROSPHERE would be available at a discount equal to 654 percent of the deal price, BREZTRI AEROSPHERE at a 98 percent discount, and AIRSUPRA at a 96 percent discount for patients purchasing directly.
On October 16, Trump announced an agreement with EMD Serono that applied to its full in vitro fertilization therapy portfolio. When used together in a typical IVF protocol, the company said eligible patients could access an 84 percent discount off list prices, potentially saving thousands of dollars per treatment cycle.
The most recent agreements, unveiled last week, involved Eli Lilly and Novo Nordisk. Novo Nordisk agreed to cut the monthly prices of {“}
]and Wegovy from roughly $1,000 and $1,350, respectively, to $350, while Eli Lilly agreed to reduce Zepbound and Orforglipron from $1,086 per month to $346. Medicare prices for those four drugs will be $245 per month.
The companies also agreed to specific price reductions on additional medications, with Novo Nordisk providing widely used insulin products, including NovoLog and Tresiba, at $35 per month, and Eli Lilly offering discounted prices on other treatments such as Emgality for migraines and Trulicity for diabetes, each reduced hundreds of dollars from their list prices.
